Free Trial

Tenet Healthcare (THC) Stock Forecast & Price Target

$138.68
+3.78 (+2.80%)
(As of 07/23/2024 ET)

Tenet Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 18 Wall Street analysts who have issued ratings for Tenet Healthcare in the last 12 months, the stock has a consensus rating of "Buy." Out of the 18 analysts, 1 has given a hold rating, 15 have given a buy rating, and 2 have given a strong buy rating for THC.

Consensus Price Target

$123.18
-11.18% Downside
High Forecast$156.00
Average Forecast$123.18
Low Forecast$85.00

According to the 18 analysts' twelve-month price targets for Tenet Healthcare, the average price target is $123.18. The highest price target for THC is $156.00, while the lowest price target for THC is $85.00. The average price target represents a forecasted downside of -11.18% from the current price of $138.68.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
15 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$123.18$120.41$100.38$77.00
Forecasted Upside-11.18% Downside19.53% Upside25.37% Upside33.67% Upside
Get Tenet Healthcare Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for THC and its competitors with MarketBeat's FREE daily newsletter.

THC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

THC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Tenet Healthcare Stock vs. The Competition

TypeTenet HealthcareMedical CompaniesS&P 500
Consensus Rating Score
3.06
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside-10.75% Downside3,096.68% Upside9.52% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/15/2024Truist Financial
1 of 5 stars
 Boost TargetBuy ➝ Buy$130.00 ➝ $155.00+16.49%
7/10/2024Barclays
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$147.00 ➝ $156.00+19.38%
7/9/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$112.00 ➝ $112.00-14.90%
6/28/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$150.00 ➝ $155.00+16.40%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$107.00 ➝ $140.00+4.67%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$153.00+16.31%
5/1/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$109.00 ➝ $136.00+16.51%
5/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$137.00 ➝ $150.00+29.29%
5/1/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$118.00 ➝ $130.00+13.23%
5/1/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$95.00 ➝ $122.00+8.64%
3/28/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$105.00 ➝ $115.00+9.72%
3/27/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$122.00+19.21%
11/14/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$95.00 ➝ $85.00+45.40%
11/9/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$98.00 ➝ $85.00+58.38%
11/1/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetStrong-Buy ➝ Strong-Buy$95.00 ➝ $90.00+67.54%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$92.00 ➝ $98.00+27.60%
8/1/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$83.00 ➝ $90.00+20.43%
12/6/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$40.00 ➝ $45.00+2.25%
10/25/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Whit Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$89.00 ➝ $55.00+40.99%
10/21/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$79.00 ➝ $64.00+71.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:22 PM ET.

THC Forecast - Frequently Asked Questions

What is Tenet Healthcare's forecast for 2024?

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Tenet Healthcare is $123.18, with a high forecast of $156.00 and a low forecast of $85.00.

Should I buy or sell Tenet Healthcare stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenet Healthcare in the last year. There is currently 1 hold rating, 15 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" THC shares.

Does Tenet Healthcare's stock price have much upside?

According to analysts, Tenet Healthcare's stock has a predicted upside of 17.76% based on their 12-month stock forecasts.

Has Tenet Healthcare been upgraded by Wall Street analysts recently?

Over the previous 90 days, Tenet Healthcare's stock had 1 upgrade by analysts.

What analysts cover Tenet Healthcare?
Do Wall Street analysts like Tenet Healthcare more than its competitors?

Analysts like Tenet Healthcare more than other "medical" companies. The consensus rating for Tenet Healthcare is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how THC compares to other companies.


This page (NYSE:THC) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners